Cerene menstrual device-maker Channel nets $14.1M in series C-1 for clinic trials
Channel Medsystems closed a series C-1 financing of $14.1 million led by insider investors. The company has developed a the Cerene physician-office cryotherapy device for heavy menstrual bleeding. Funds will be applied to efforts to seek FDA approval of the device, and for commercialization at a later date.
Columbia researchers reveal novel technique to link 'dark genome' to genetic diseases
Elucidating the role of genetics in understanding disease is a driving force for the diagnostic and biopharmaceutical industries. But, until now, much of the human genome has remained largely a mystery. Scientists have long focused on the portion that codes for proteins but that represents only 2 percent of the human genome. Researchers at Columbia University Medical Center have developed a new technique, known as Orion, which interrogates the noncoding 98 percent, the so-called 'dark genome.'
Vascular Dynamics receives approval for pivotal trial to treat resistant hypertension
Vascular Dynamics Inc. (VDI), a private company, said the FDA has approved an IDE application to initiate a pivotal trial for the Mobiushd system in the treatment of resistant hypertension. The Controlling and Lowering Blood Pressure with Mobiushd (CALM) 2 trial is a multicenter, prospective, randomized, double-blind, sham-controlled pivotal study.